The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | The potential health economic benefits of T-cell redirecting therapy in myeloma
Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the recent developments in myeloma with T-cell redirecting therapy, highlighting the unprecedented response rates and durable responses achieved with this approach. Dr Lee notes that the durability of responses and potential for de-escalation of dosing frequency over time may lead to a positive health economic outcome compared with conventional agents. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think one of the really gratifying things from recent developments in myeloma with T-cell redirecting therapy is that we’re seeing not only unprecedented response rates, but also durable responses. And so when you think about the number needed to treat to actually attain an excellent response, a durable response, then it makes perhaps more sense from a health economic standpoint. Because eventually, for instance, with the bispecific T-cell antibodies, we may go with a more intense dosing schedule early on, perhaps weekly dosing, but then eventually there’s de-escalation of the frequency of dosing to every other week, maybe every four-week dosing...
I think one of the really gratifying things from recent developments in myeloma with T-cell redirecting therapy is that we’re seeing not only unprecedented response rates, but also durable responses. And so when you think about the number needed to treat to actually attain an excellent response, a durable response, then it makes perhaps more sense from a health economic standpoint. Because eventually, for instance, with the bispecific T-cell antibodies, we may go with a more intense dosing schedule early on, perhaps weekly dosing, but then eventually there’s de-escalation of the frequency of dosing to every other week, maybe every four-week dosing. So when thinking about the totality of the healthcare resource utilization of the delivery of these agents, ultimately I think it becomes a positive compared to other conventional agents that we historically have offered to patients in this setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
